-

INVESTOR ALERT: Kirby McInerney LLP Announces the Filing of a Securities Class Action Lawsuit Against Fluidigm Corporation

NEW YORK--(BUSINESS WIRE)--The law firm of Kirby McInerney LLP announces that a class action lawsuit has been filed in the U.S. District Court for the Northern District of California on behalf of those who acquired Fluidigm Corporation (“Fluidigm” or the “Company”) (NASDAQ: FLDM) securities during the period from February 7, 2019 through November 5, 2019, inclusive (the “Class Period”). Investors have until November 23, 2020 to apply to the Court to be appointed as lead plaintiff in the lawsuit.

The complaint filed in this class action alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company’s business, operations, and prospects. Specifically, Defendants failed to disclose to investors: (1) that Fluidigm was experiencing longer sales cycles; (2) that, as a result, Fluidigm’s revenue was reasonably likely to decline; and (3) that, as a result of the foregoing, Defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

On August 1, 2019, Fluidigm reported second quarter 2019 revenue of $28.2 million, well below analysts’ expectations of $32 million, citing weakness in its microfluidics segment. On this news, the Company’s share price fell $4.10, or 34%, to close at $8.05 per share on August 2, 2019, thereby injuring investors. Then, on November 5, 2019, after the market closed, Fluidigm reported that third quarter 2019 revenue declined 8.5% year-over-year primarily due to mass cytometry instrument sales. On this news, the Company’s share price fell $2.60, or 51%, to close at $2.51 per share on November 6, 2019, thereby injuring investors further.

If you acquired Fluidigm securities, have information, or would like to learn more about these claims, please contact Thomas W. Elrod of Kirby McInerney at 212-371-6600, by email at investigations@kmllp.com, or by filling out this contact form, to discuss your rights or interests with respect to these matters without any cost to you.

Kirby McInerney is a New York-based plaintiffs’ law firm concentrating in securities, antitrust, and whistleblower litigation. The firm’s efforts on behalf of shareholders in securities litigation have resulted in recoveries totaling billions of dollars. Additional information about the firm can be found at Kirby McInerney’s website: www.kmllp.com.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Contacts

Kirby McInerney LLP
Thomas W. Elrod, Esq., (212) 371-6600
investigations@kmllp.com
www.kmllp.com

Kirby McInerney LLP

NASDAQ:FLDM

Release Versions
$Cashtags

Contacts

Kirby McInerney LLP
Thomas W. Elrod, Esq., (212) 371-6600
investigations@kmllp.com
www.kmllp.com

Social Media Profiles
More News From Kirby McInerney LLP

JEFFERIES FINANCIAL GROUP, INC. INVESTOR ALERT: Kirby McInerney LLP Announces Investigation Into Potential Securities Fraud

NEW YORK--(BUSINESS WIRE)--The law firm of Kirby McInerney LLP is investigating potential claims against Jefferies Financial Group, Inc. (“Jefferies” or the “Company”) (NYSE:JEF). The investigation concerns whether the Company and/or members of its senior management may have violated federal securities laws or engaged in other unlawful business practices.[LEARN MORE ABOUT THE INVESTIGATION]What Happened?On June 25, 2026, Jefferies reported quarterly results showing weaker asset-management fees a...

ALIGNMENT HEALTHCARE, INC. INVESTOR ALERT: Kirby McInerney LLP Announces Investigation Into Potential Securities Fraud

NEW YORK--(BUSINESS WIRE)--The law firm of Kirby McInerney LLP is investigating potential claims against Alignment Healthcare, Inc. (“Alignment Healthcare” or the “Company”) (NASDAQ:ALHC). The investigation concerns whether the Company and/or members of its senior management may have violated federal securities laws or engaged in other unlawful business practices.[LEARN MORE ABOUT THE INVESTIGATION]What Happened?On July 8, 2026, it was reported that a former executive at Alignment Healthcare fil...

UNCY INVESTOR ALERT: Kirby McInerney LLP Investigates Potential Claims Involving Unicycive Therapeutics, Inc.

NEW YORK--(BUSINESS WIRE)--The law firm of Kirby McInerney LLP continues its investigation on behalf of Unicycive Therapeutics, Inc. (“Unicycive” or the “Company”) (NASDAQ:UNCY) investors concerning the Company’s and/or members of its senior management’s possible violation of the federal securities laws and other unlawful business practices.[LEARN MORE ABOUT THE INVESTIGATION]What Happened?On June 30, 2026, Unicycive announced that the FDA had issued a second Complete Response Letter (“CRL”) reg...
Back to Newsroom